MRS

Severely Stressful Events Worsen Symptoms of Long COVID

Retrieved on: 
Mercoledì, Novembre 9, 2022
Trauma, NYU Langone Health, Yale School of Medicine, Cognition, NYU, Frontera, Anxiety, Ageing, Journal of the Neurological Sciences, PLOS, Hospital, Patient, PLOS One, JNS, Department, Brookings Institution, Brain, Population, Death, Mid-Columbia Medical Center, New York University Grossman School of Medicine, Sleep, Brookings, Journal, Montreal, Occupational therapy, Headache, Brown University School of Public Health, COVID-19, Food, Degenerative disease, COVID, Disability, NIH, Department of Neurology, Xuanwu hospital, Fatigue, Barthel scale, Depression, Montreal Cognitive Assessment, Woman, Rankine scale, MRS, Research, Quality of life, Risk, Adult, Pharmaceutical industry, Medical device, Neurology, MD

"Therapies that lessen the trauma of the most stress-inducing life events need to be a central part of treatment for long COVID, with more research needed to validate the best approaches."

Key Points: 
  • "Therapies that lessen the trauma of the most stress-inducing life events need to be a central part of treatment for long COVID, with more research needed to validate the best approaches."
  • Because there is no current biological definition long COVID, many studies lump disparate symptoms into what is currently a blanket diagnosis, and without an assessment of clinical relevance, says Frontera.
  • The most severely affected patients had higher rates of disability, worse measures of anxiety, depression, fatigue and sleep disorders.
  • The Brookings Institution estimated in August 2022 that roughly 16 million working-age Americans (aged 18 to 65) have long COVID, out of which 2 to 4 million are out of work due to long COVID.

CyberOptics 3D MRS® Sensing Technology Surpasses 32 Awards

Retrieved on: 
Lunedì, Novembre 7, 2022
Packaging, Semiconductor, Technology, Manufacturing, Audio, Video, Hardware, SMT, Company, SPI, Metrology, Corporation, Multimedia, AOI, Industry, CMM, NDSN, Electronics, Motor vehicle, Nasdaq, Technology, Testing and inspection of diving cylinders, MRS, Nordson Corporation, GTA, Printed circuit board

Nordson Corporation (Nasdaq: NDSN) today announced that it received three 2022 Global Technology Awards in the categories of Metrology and AOI Inspection Systems for its CyberOptics SQ3000+ and SPI Inspection Systems for its new CyberOptics Dual-Mode Multi-Reflection Suppression (MRS) sensor-enabled SE3000 SPI system.

Key Points: 
  • Nordson Corporation (Nasdaq: NDSN) today announced that it received three 2022 Global Technology Awards in the categories of Metrology and AOI Inspection Systems for its CyberOptics SQ3000+ and SPI Inspection Systems for its new CyberOptics Dual-Mode Multi-Reflection Suppression (MRS) sensor-enabled SE3000 SPI system.
  • The new sensor is an extension of the proprietary MRS sensor portfolio that provides industry-leading performance in semiconductor and SMT markets.
  • MRS sensor technology provides the ultimate combination of speed, resolution and accuracy while meticulously identifying and rejecting reflection-based distortions caused by shiny components and surfaces.
  • The Global Technology Awards have recognized the very best new innovations in the printed circuit assembly and packaging industries since 2005.

Pharmazz Inc. Presents Positive Results of Phase III Clinical Trial Demonstrating Sovateltide’s Efficacy as a Treatment for Acute Cerebral Ischemic Stroke

Retrieved on: 
Lunedì, Ottobre 31, 2022
Board, TPA, Stroke, BI, Magnetic resonance imaging, Consciousness, Patient, Congress, Mortality, CT, Critical care, Adult, GLOBE, Infarction, MRS, Recurrence, Quality of life, NIHSS, Rankin, Incidence, Standard of care, Therapy, MRI, Pharmaceutical industry, Medical imaging

WILLOWBROOK, Ill., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (“Pharmazz”), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke. Sovateltide demonstrated statistically significant and clinically meaningful improvements in multiple neurological outcomes in patients with acute cerebral ischemic stroke and was well tolerated. The trial results were presented in an oral session at the 14th World Stroke Congress in Singapore.

Key Points: 
  • WILLOWBROOK, Ill., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Pharmazz, Inc. (Pharmazz), a biopharmaceutical company focused on developing and commercializing novel therapeutics to treat patients in critical care, today presented positive results of its Phase III clinical trial evaluating sovateltide as a treatment for acute ischemic stroke.
  • Sovateltide demonstrated statistically significant and clinically meaningful improvements in multiple neurological outcomes in patients with acute cerebral ischemic stroke and was well tolerated.
  • The trial results were presented in an oral session at the 14th World Stroke Congress in Singapore.
  • Results of this trial make us highly encouraged regarding the potential of sovateltide to be a clinically meaningful treatment for patients suffering from acute ischemic stroke.

Boryung, Axiom Space, and Starburst Aerospace Announce Six Winners From The Inaugural 2022 Care In Space Challenge

Retrieved on: 
Martedì, Ottobre 25, 2022
Axiom Space, CFO, Therapy, Program, Entrepreneurship, PVD, Starburst, CEO, Biology, Travel, Vital signs, International Space Station, Aviation, Solution, Astronaut, Neurological disorder, Achievement, MBA, Humanism, Lists of diseases, Executive, Mentorship, MRS, In vivo magnetic resonance spectroscopy, CTO, ATS, Strategy, Development, Government, Diagnosis, Respiration, CIS, Health, Contract, PMP, Research, Ministry of Education (Malaysia), Ecosystem, CPA, Interactive storytelling, Commerce, Axiom Orbital Segment, Terrestrial, COO, Patient, Hospital, Business, UCLA, Face, Scientific research on the International Space Station, Radar, Minneapolis Veterans Affairs Health Care System, Pharmaceutical industry, Video game, Medical device, Axiom

EL SEGUNDO, Calif., Oct. 25, 2022 /PRNewswire/ -- Boryung, an investment and management company, Axiom Space, the world's leading commercial space station company, and Starburst Aerospace, the leading global aerospace and defense startup accelerator and strategic advisory practice, have officially announced the six startup winners of the inaugural Care In Space (CIS) Challenge.

Key Points: 
  • EL SEGUNDO, Calif., Oct. 25, 2022 /PRNewswire/ -- Boryung , an investment and management company, Axiom Space , the world's leading commercial space station company, and Starburst Aerospace , the leading global aerospace and defense startup accelerator and strategic advisory practice, have officially announced the six startup winners of the inaugural Care In Space (CIS) Challenge.
  • Hosted by Boryung in collaboration with Axiom Space and Starburst Aerospace, the CIS Challenge aims to advance the future of space health and the next generation of pharmaceutical, bioscience, and medtech development in space.
  • Space health encompasses all stages of the 'Healthcare Journey' from initial monitoring and diagnosis, to treatment, therapeutics, and continuing care.
  • The 2022 Care In Space Challenge Winners are Advanced TeleSensors, Deep Space Biology, Myelin-H, Nano PharmaSolutions, ViBo Health, and Xtory.

Cellevolve Bio Receives FDA Clearance of IND Application and Orphan Drug Designation for CE-VST01-JC for the Treatment of Progressive Multifocal Leukoencephalopathy (PML)

Retrieved on: 
Martedì, Ottobre 25, 2022
SAN, Human polyomavirus 2, Therapy, IND, Science, EMA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, JC, Patient, Degenerative disease, Progressive multifocal leukoencephalopathy, Food, Company, Immunodeficiency, CEO, NORD, Tropical disease, Social media, Safety, CNS, PML, Demyelinating disease, JCV, FDA, Central nervous system, MRS, Vaccine, Pharmaceutical industry, EU

CE-VST01-JC also received FDA orphan drug designation.

Key Points: 
  • CE-VST01-JC also received FDA orphan drug designation.
  • "We are thrilled to have received IND clearance to begin our Phase 2 clinical study," said Derrell Porter, M.D., Founder and CEO, Cellevolve.
  • PML is a demyelinating disease of the central nervous system (CNS) caused by JCV and occurs in immunocompromised patients.
  • There are no FDA or EMA approved treatments for this condition, which affects ~ 4,000 individuals in the US and Europe annually.

Over Two Thirds of Companies Worried About Their Ability to Catch Exam Cheats

Retrieved on: 
Mercoledì, Ottobre 19, 2022
Security, Data Management, Technology, Continuing, Human Resources, University, Consulting, Education, Banking, Business, Training, Accounting, Professional Services, Software, Internet, Culture, Development, Prevalence, Head, VP, Digital learning, Certification, Organization, Research, Market Research Society, Translation, Senior, Privacy and the US government, MRS, Northwestern University Master of Product Design and Development Management, Government, Digital, Fraud, L&D, ESOMAR, Public relations, Risk management, Casino, Management, Learning

New research released today from leading assessment software provider Questionmark , shows that just over two thirds (72%) of US businesses are concerned about their ability to detect cheating during an exam.

Key Points: 
  • New research released today from leading assessment software provider Questionmark , shows that just over two thirds (72%) of US businesses are concerned about their ability to detect cheating during an exam.
  • Relying on honesty culture is not going to cut it when it comes to high stakes exams and leaves organizations dangerously exposed.
  • While organizations have concerns around their ability to catch those cheating, many have zero tolerance measures in place.
  • To date, weve been trusted by more than 2,500 customers worldwide and deliver more than 18 million assessments a year.

BridgeBio Pharma Presents Updated Positive Data from its BBP-812 Canavan Disease Gene Therapy Program at the 51st Annual Meeting of the Child Neurology Society

Retrieved on: 
Giovedì, Ottobre 13, 2022
European Medicines Agency, LinkedIn, Aspartoacylase, Lists of diseases, Time, U.S. Securities and Exchange Commission, Drug Quality and Security Act, Orphan, Canavan disease, Disease, SEC, Securities Exchange Act of 1934, CSF, Science, Traffic barrier, Axon, Annual report, Fast track (FDA), Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Patient, Urine, IV, Twitter, N-Acetylaspartic acid, Cell, Securities Act of 1933, ASPA, Food, Neuron, Mutation, AAV, Toxicity, MRS, Safety, Exchange, Survival, Clinical trial, Environment, NAA, Brain, COVID-19, Cancer, Risk, Pharmaceutical industry

PALO ALTO, Calif., Oct. 13, 2022 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented promising pharmacodynamic, tolerability and preliminary functional efficacy data from the first three participants dosed in CANaspire, its Phase 1/2 clinical trial of BBP-812, an investigational intravenous (IV) adeno-associated virus serotype 9 (AAV9) gene therapy for the treatment of Canavan disease. An update on the CANinform natural history study, which continues to enroll new participants globally, was also presented. Canavan disease is an ultra-rare and fatal disease with no approved therapies.   New data from the third CANaspire participant are consistent with the first two treated children:

Key Points: 
  • BBP-812 is an investigational AAV9 gene therapy for Canavan disease.
  • Using AAV gene therapy, BridgeBio seeks to deliver functional copies of the ASPA gene throughout the body and into the brain, potentially correcting the disease at its source.
  • Preclinical proof-of-concept results have shown the approach restores survival and normal motor function in Canavan disease models.
  • Affecting approximately 1,000 children in the United States and European Union, Canavan disease is an ultra-rare, disabling and fatal disease with no approved therapy.

Aclarion To Present at The LD Micro Main Event XV

Retrieved on: 
Mercoledì, Ottobre 12, 2022
Physician, Software as a service, NASDAQ, Intelligence, LD, Low back pain, Index, MRI, Company, MRS, Pain, Main Event, In vivo magnetic resonance spectroscopy, Biomarker, Algorithm, Medical imaging

Presentation on Tuesday, October 25th at 9:00 AM PT

Key Points: 
  • The 2022 LD Micro Main Event XV will be held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 25th to the 27th.
  • The festivities will run from 7:30 AM PT - 5:30 PM PT on the 25th and 26th, with a half day on Thursday the 27th.
  • This three-day, investor conference is expected to feature around 200+ companies, presenting in half-hour increments, as well as private meetings.
  • LD Micro aims to be the most crucial resource in the micro-cap world.

Aleut to Remediate Munitions and Explosives of Concern at the Former Camp Howze Site

Retrieved on: 
Martedì, Ottobre 4, 2022
Federal Employers Liability Act, Congress, Corps, Superfund, Dangerous, Agriculture, LLC, USACE, Compensation, Program, The Aleut Corporation, ARS, U.S. Army Corps of Engineers, Europe District, MEC, Small Business Administration, MRS, SBA, Environment, CERCLA, TAC, ANCSA, Hazardous waste

COOKE COUNTY, Texas, Oct. 4, 2022 /PRNewswire/ -- ARS Aleut Remediation, LLC (Aleut) was awarded a contract by the U.S. Army Corps of Engineers (USACE) Tulsa District to perform removal of Munitions and Explosives of Concern (MEC) and restoration services for the former Camp Howze Munitions Response Site (MRS) 10.

Key Points: 
  • COOKE COUNTY, Texas, Oct. 4, 2022 /PRNewswire/ -- ARS Aleut Remediation, LLC (Aleut) was awarded a contract by the U.S. Army Corps of Engineers (USACE) Tulsa District to perform removal of Munitions and Explosives of Concern (MEC) and restoration services for the former Camp Howze Munitions Response Site (MRS) 10.
  • Aleut will perform the work under the guidelines of the Comprehensive Environmental Response, Compensation, and Liability Act (CERCLA), also known as Superfund.
  • Camp Howze was closed in 1946 and is now privately-owned forest and grasslands used for agriculture, cattle grazing, and hunting.
  • ARS Aleut Remediation, LLC is a wholly owned subsidiary of Aleut Federal, LLC , a holding company for federal subsidiaries of The Aleut Corporation (TAC).

CyberOptics Receives Mexico Technology Award for Dual-Mode MRS® sensor-enabled SE3000™ SPI System

Retrieved on: 
Giovedì, Settembre 22, 2022
Other Manufacturing, Technology, Semiconductor, Packaging, Engineering, Other Technology, Software, Manufacturing, Machinery, Hardware, SPI, CYBE, Inspection, Electronics, 3D, COVID-19, Company, U.S. Securities and Exchange Commission, CEO, Technology, SMT, NASDAQ, OEM, Security (finance), MX, MRS, Depression, Printed circuit board

CyberOptics Corporation (NASDAQ: CYBE), a leading global developer and manufacturer of high-precision 3D sensing technology solutions, today announced that it received a 2022 Mexico Technology Award in the category of Inspection Solder Paste Inspection (SPI) for its new Dual-Mode Multi-Reflection Suppression (MRS) sensor-enabled SE3000 SPI system.

Key Points: 
  • CyberOptics Corporation (NASDAQ: CYBE), a leading global developer and manufacturer of high-precision 3D sensing technology solutions, today announced that it received a 2022 Mexico Technology Award in the category of Inspection Solder Paste Inspection (SPI) for its new Dual-Mode Multi-Reflection Suppression (MRS) sensor-enabled SE3000 SPI system.
  • The award was announced during a ceremony that took place Wednesday, Sept. 21, 2022 during SMTA Guadalajara in Mexico.
  • The new Dual-Mode MRS sensor for the SE3000 SPI system provides maximum flexibility for dedicated solder paste inspection applications, with one mode for high-speed inspection and another mode for high resolution inspection.
  • Were delighted to receive our 29th award related to our MRS sensor technology, said Dr. Subodh Kulkarni, President and CEO, CyberOptics Corporation.